TherapeuticsMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, revenue was USD 68.81 million compared to USD 68.27 million a year ago. Net income was USD 34.3 million compared to net loss of USD 129.46 million a year ago. Basic earnings per share from continuing operations was USD 3.86 compared to basic loss per share from continuing operations of USD 16.68 a year ago. Diluted earnings per share from continuing operations was USD 3.73 compared to diluted loss per share from continuing operations of USD 16.68 a year ago.